lam research corp. - LRCX
LRCX
Close Chg Chg %
73.13 -0.49 -0.67%
Closed Market
72.64
-0.49 (0.67%)
Volume: 8.67M
Last Updated:
Nov 22, 2024, 4:00 PM EDT
Company Overview: lam research corp. - LRCX
LRCX Key Data
| Open $72.61 | Day Range 71.60 - 73.27 |
| 52 Week Range 68.72 - 113.00 | Market Cap $94.09B |
| Shares Outstanding 1.29B | Public Float 1.28B |
| Beta 1.49 | Rev. Per Employee N/A |
| P/E Ratio 23.66 | EPS $3.10 |
| Yield 113.50% | Dividend $0.23 |
| EX-DIVIDEND DATE Dec 11, 2024 | SHORT INTEREST N/A |
| AVERAGE VOLUME 11.85M |
LRCX Performance
| 1 Week | 3.70% | ||
| 1 Month | -6.49% | ||
| 3 Months | -14.28% | ||
| 1 Year | 1.24% | ||
| 5 Years | 177.27% |
LRCX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
34
Full Ratings ➔
About lam research corp. - LRCX
Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.
LRCX At a Glance
Lam Research Corp.
4650 Cushing Parkway
Fremont, California 94538
| Phone | 1-510-572-0200 | Revenue | 14.91B | |
| Industry | Industrial Machinery | Net Income | 3.83B | |
| Sector | Producer Manufacturing | Employees | 17,450 | |
| Fiscal Year-end | 06 / 2025 | |||
| View SEC Filings |
LRCX Valuation
| P/E Current | 23.664 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 36.72 |
| Price to Sales Ratio | 9.43 |
| Price to Book Ratio | 16.258 |
| Price to Cash Flow Ratio | 30.212 |
| Enterprise Value to EBITDA | 29.877 |
| Enterprise Value to Sales | 9.391 |
| Total Debt to Enterprise Value | 0.038 |
LRCX Efficiency
| Revenue/Employee | 854,176.848 |
| Income Per Employee | 219,356.562 |
| Receivables Turnover | 5.917 |
| Total Asset Turnover | 0.794 |
LRCX Liquidity
| Current Ratio | 2.97 |
| Quick Ratio | 1.997 |
| Cash Ratio | 1.348 |
LRCX Profitability
| Gross Margin | 47.608 |
| Operating Margin | 29.02 |
| Pretax Margin | 29.253 |
| Net Margin | 25.68 |
| Return on Assets | 20.40 |
| Return on Equity | 45.706 |
| Return on Total Capital | 27.716 |
| Return on Invested Capital | 28.751 |
LRCX Capital Structure
| Total Debt to Total Equity | 61.726 |
| Total Debt to Total Capital | 38.167 |
| Total Debt to Total Assets | 28.12 |
| Long-Term Debt to Equity | 55.06 |
| Long-Term Debt to Total Capital | 34.045 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Lam Research Corp. - LRCX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 14.63B | 17.18B | 17.43B | 14.91B | |
Sales Growth
| +45.66% | +17.48% | +1.42% | -14.47% | |
Cost of Goods Sold (COGS) incl D&A
| 7.82B | 9.34B | 9.58B | 7.81B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 307.15M | 333.74M | 342.43M | 359.70M | |
Depreciation
| 236.55M | 255.74M | 290.93M | 303.40M | |
Amortization of Intangibles
| 70.60M | 78.00M | 51.50M | 56.30M | |
COGS Growth
| +43.99% | +19.42% | +2.49% | -18.45% | |
Gross Income
| 6.80B | 7.84B | 7.85B | 7.10B | |
Gross Income Growth
| +47.63% | +15.25% | +0.15% | -9.61% | |
Gross Profit Margin
| +46.50% | +45.62% | +45.05% | +47.61% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 2.33B | 2.49B | 2.56B | 2.77B | |
Research & Development
| 1.49B | 1.60B | 1.73B | 1.90B | |
Other SG&A
| 833.50M | 883.30M | 832.89M | 868.25M | |
SGA Growth
| +20.33% | +6.90% | +2.91% | +8.23% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (7.06M) | (14.36M) | 129.86M | 61.56M | |
EBIT after Unusual Expense
| 4.48B | 5.36B | 5.16B | 4.26B | |
Non Operating Income/Expense
| 98.47M | 12.89M | 135.30M | 281.55M | |
Non-Operating Interest Income
| 19.69M | 15.21M | 138.98M | 251.94M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 208.60M | 184.76M | 186.46M | 185.24M | |
Interest Expense Growth
| +17.56% | -11.43% | +0.92% | -0.66% | |
Gross Interest Expense
| 208.60M | 184.76M | 186.46M | 185.24M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 4.37B | 5.19B | 5.11B | 4.36B | |
Pretax Income Growth
| +69.74% | +18.81% | -1.62% | -14.66% | |
Pretax Margin
| +29.89% | +30.22% | +29.32% | +29.25% | |
Income Tax
| 462.35M | 587.83M | 598.28M | 532.45M | |
Income Tax - Current - Domestic
| 451.08M | 641.10M | 573.50M | 586.19M | |
Income Tax - Current - Foreign
| 162.74M | 204.16M | 196.84M | 143.59M | |
Income Tax - Deferred - Domestic
| (147.85M) | (245.99M) | (138.99M) | (201.36M) | |
Income Tax - Deferred - Foreign
| (3.62M) | (11.45M) | (33.07M) | 4.02M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 3.91B | 4.61B | 4.51B | 3.83B | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 3.91B | 4.61B | 4.51B | 3.83B | |
Net Income Growth
| +73.57% | +17.83% | -2.05% | -15.14% | |
Net Margin Growth
| +26.72% | +26.80% | +25.89% | +25.68% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 3.91B | 4.61B | 4.51B | 3.83B | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 3.91B | 4.61B | 4.51B | 3.83B | |
EPS (Basic)
| 2.7216 | 3.2919 | 3.3298 | 2.9128 | |
EPS (Basic) Growth
| +75.03% | +20.95% | +1.15% | -12.52% | |
Basic Shares Outstanding
| 1.44B | 1.40B | 1.35B | 1.31B | |
EPS (Diluted)
| 2.6896 | 3.2748 | 3.3209 | 2.8999 | |
EPS (Diluted) Growth
| +78.08% | +21.76% | +1.41% | -12.68% | |
Diluted Shares Outstanding
| 1.45B | 1.41B | 1.36B | 1.32B | |
EBITDA
| 4.78B | 5.68B | 5.63B | 4.69B | |
EBITDA Growth
| +62.54% | +18.89% | -0.91% | -16.82% | |
EBITDA Margin
| +32.69% | +33.08% | +32.32% | +31.43% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 95.093 | |
| Number of Ratings | 34 | Current Quarters Estimate | 0.879 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 3.559 | |
| Last Quarter’s Earnings | 0.86 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 3.03 | Next Fiscal Year Estimate | 4.21 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 24 | 23 | 27 | 22 |
| Mean Estimate | 0.88 | 0.88 | 3.56 | 4.21 |
| High Estimates | 0.92 | 0.95 | 3.82 | 4.75 |
| Low Estimate | 0.83 | 0.82 | 3.36 | 3.61 |
| Coefficient of Variance | 2.11 | 3.58 | 2.69 | 7.60 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 19 | 19 | 17 |
| OVERWEIGHT | 3 | 3 | 4 |
| HOLD | 12 | 12 | 11 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Lam Research Corp. - LRCX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Lam Research Corp. - LRCX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 13, 2024 | Eric K. Brandt Director | 287,070 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 13, 2024 | Sohail U. Ahmed Director | 2,950 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 13, 2024 | Mark Fields Director | 737 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 13, 2024 | Michael R. Cannon Director | 189,740 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 13, 2024 | Bethany Jean Mayer Director | 2,950 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 13, 2024 | Ho Kyu Kang Director | 8,693 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 13, 2024 | Jyoti K. Mehra Director | 16,840 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 13, 2024 | Abhijit Y. Talwalkar Director | 108,360 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 13, 2024 | John M. Dineen Director | 7,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 13, 2024 | Mark Fields Director | 3,687 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 8, 2024 | Bethany Jean Mayer Director | 28,930 | Other acquisition or disposition | 0.00 |
| Oct 2, 2024 | Sesha Varadarajan Senior Vice President | 16,454 | Bona fide gift | 0.00 |
| Jul 16, 2024 | Neil J Fernandes Senior Vice President | 5,237 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1056.99 per share | 5,535,456.63 |
| May 7, 2024 | George Milford Schisler Chief Legal Officer | 5,661 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $908.21 per share | 5,141,376.81 |
| May 1, 2024 | Patrick James Lord Executive Vice President | 4,454 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $921.54 per share | 4,104,539.16 |
| Apr 3, 2024 | Christina Corrreia CVP , Chief Accounting Officer | 5,541 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $972.03 per share | 5,386,018.23 |
| Mar 20, 2024 | Sesha Varadarajan Senior Vice President | 16,595 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $913.99 per share | 15,167,664.05 |
| Mar 14, 2024 | Patrick James Lord Executive Vice President | 9,492 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $925.29 per share | 8,782,852.68 |
| Mar 14, 2024 | Patrick James Lord Executive Vice President | 9,692 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $924.26 per share | 8,957,927.92 |
| Mar 14, 2024 | Patrick James Lord Executive Vice President | 8,439 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $927 per share | 7,822,953.00 |